AP NEWS

The U.S. Onychomycosis Market 2018 - Profiles for Valeant Pharmaceuticals, Pfizer, Novartis and Johnson & Johnson - ResearchAndMarkets.com

October 1, 2018
The “The U.S. Onychomycosis Market: Size, Trends and Forecasts (2018 Edition)” report has been added to ResearchAndMarkets.com’s offering.

The U.S. onychomycosis market (prescription drugs) has increased with a healthy growth rate over the years and is expected to increase further during the forecasted period.

The U.S. onychomycosis market is supported by various growth drivers, such as rising per capita healthcare expenditure, increasing diabetic patients, ageing population, introduction of new drugs, etc. Yet, the market faces certain challenges, such as, reimbursements, low awareness, side effects, etc.

Key Topics Covered

1. Executive Summary

2. Introduction

3. Global Market Analysis

4. U.S. Market Analysis

5. Competitive Landscape

6. Company Profiles

Valeant PharmaceuticalsPfizer Inc.Novartis AGJohnson & Johnson

For more information about this report visit https://www.researchandmarkets.com/research/hcgc2m/the_u_s?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20181001005419/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Infectious Diseases Drugs

KEYWORD: UNITED STATES NORTH AMERICA

INDUSTRY KEYWORD: HEALTH INFECTIOUS DISEASES PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 10/01/2018 06:18 AM/DISC: 10/01/2018 06:19 AM

http://www.businesswire.com/news/home/20181001005419/en

AP RADIO
Update hourly